One study enrolling 322 patients with locally advanced or advanced NSCLC who progressed during EGFR-TKI therapy reported a median PFS of 7.06 months in the ivonescimab plus chemotherapy group versus 4.08 months in the chemotherapy-only group (41). Here, EGFR is linked to non-small cell lung carcinoma.